Incendia's clinical trial is evaluating a DDR1 inhibitor called PRTH-101 that is given once every 21 days in combination with pembrolizumab.
DDR1, the Tumor Microenvironment, and PRTH-101
DDR1 (discoidin domain receptor 1) is a protein that binds to collagen and plays a key role in the way your cells move and grow. In tumors, DDR1 is an element of the tumor microenvironment.
The tumor microenvironment is a complex ecosystem of cells and other non-cellular components that surround and penetrate a solid tumor. The tumor microenvironment presents a structural and biochemical barrier that can block immune cell activity, thereby diminishing the effectiveness of treatments, including immunotherapies.
PRTH-101 binds to and inhibits DDR1, aiming to disrupt the tumor microenvironment's protection of tumors from treatment and immune cell activity.
There is no placebo in this study.
NSCLC Clinical Trial Information
PRTH-101-0001 is an open-label Phase 1 clinical trial for adults that have been diagnosed with metastatic or advanced solid tumors.
This is a two-part trial:
- Part 1 (Completed) – here the goal is to find the optimal dose of PRTH-101 when given alone and in combination with pembrolizumab.
- Part 2 (Open) – after the optimal dose of PRTH-101 is selected, the goal is to evaluate anti-tumor activity of PRTH-101 alone and in combination with pembrolizumab.
PRTH-101-0001 is currently enrolling participants with PD-L1 Negative or Low NSCLC who will receive PRTH-101 in combination with pembrolizumab.
You can view this site on clinicaltrials.gov, using the study identifier NCT05753722
Check your Eligibility
You may be eligible to participate if you meet these requirements.
You are an adult 18 years or older
You have metastatic or advanced NSCLC that cannot be surgically removed
You are PD-L1 negative or low
Where is the Incendia NSCLC Clinical Trial taking place?
The trial will take place at several locations across the United States.
You may be eligible for all travel expenses and lodging reimbursement based on the individual sites below.
Please contact the nearest study center below for additional information.
Connecticut
Yale Cancer Center
333 Cedar Street
New Haven, CT 06520
Contact:
Priscilla W. Stéve, MBA, CCRP
203-464-5564
Clinical Trials Research RN
Texas
MD Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030
Contact:
Julia A. Moore, RN
832-710-1873
Study Coordinator/Nurse
NEXT San Antonio
2829 Babcock Road,
San Antonio, TX 78229
Contact:
Jordan Georg
210-580-9521
Clinical Trial Navigator
NEXT Dallas
6750 North MacArthur Blvd.
Irving, TX 75039
Contact:
NEXT Texas Referrals
832-710-1873
nxt_txreferrals@nextoncology.com
NEXT Houston
7500 Fannin Street
Houston, TX 77054
Contact:
Emma Morales
832-384-7912
Clinical Trial Navigator
Virginia
NEXT Virginia
8613 US 29,
Fairfax, VA 22031
Contact:
Maybelle De La Rosa
703-783-4518
New Patient Scheduler
*Additional locations opening soon
Frequently Asked Questions
What is a clinical trial?
A clinical trial is a research study conducted with patients and designed to evaluate the safety and effectiveness of a new treatment. A trial helps determine whether a new therapy is safe and works as intended.
Will I be reimbursed for travel and lodging?
The drug sponsor may cover transportation and lodging costs associated with study visits for the participant and a caregiver. This is determined by the individual clinical trial sites. Contact the site closest to you for additional information.
What if I do not see a location near me?
You may be eligible for all travel expenses and lodging reimbursement based on the individual sites listed above. Please contact the nearest site for more information.
Who is conducting the trial?
The sponsor of this clinical trial is Incendia Therapeutics, Inc.
